Filing Flows › Niagen Bioscience (NAGE) › Q2 2026
Niagen Bioscience (NAGE) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Niagen Bioscience (NAGE) reported revenue of $29.8M for the second quarter 2026 (Q2 2026), -4% from a year earlier and -5% from the quarter before. Operating margin was 2.4%, net earnings $963K (3.2% of revenue).
Niagen Bioscience, Q2 2026: revenue $29.8M (-4% year over year), operating margin 2.4%, net earnings $963K, operating cash flow $2.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29.8M | -5% | -4% |
| Gross profit | $19.3M | -3% | -5% |
| Operating profit | $700K | -56% | -78% |
| Net earnings | $963K | -85% | -73% |
| Operating cash flow | $2.8M | — | +122% |
What changed
Revenue was $29.8M in Q2 2026, down 4% year over year and down 5% from the previous quarter. Consumer Products segment was the largest line at 81% of revenue. Ingredients segment lost $2.2M year over year (down 29%), 168% of the total change.
Gross margin was 64.8%, down 0.2 points from Q2 2025. Operating profit was $700K, a 2.4% margin (down 7.9 points year over year). Operating expenses grew 9% against a revenue fall of 4%. The fastest-growing cost line was Sales & marketing (+23%). Net earnings were $1.0M, down 73% year over year. The effective tax rate was 9.9%. Non-operating items added $369K, 35% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $2.8M (up 122% year over year), 288% of net earnings. Non-cash charges added back $291K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $205K.
Questions
What was Niagen Bioscience's revenue in the second quarter 2026?
Niagen Bioscience (NAGE) reported revenue of $29.8M for the second quarter 2026 (Q2 2026), -4% from a year earlier and -5% from the quarter before.
Was Niagen Bioscience profitable in the second quarter 2026?
Operating profit was $700K (2.4% of revenue) and net earnings $963K.
Source: Niagen Bioscience 10-Q on SEC EDGAR.